JP4683724B2 - 細菌胞子を含めた細菌の不活化方法 - Google Patents
細菌胞子を含めた細菌の不活化方法 Download PDFInfo
- Publication number
- JP4683724B2 JP4683724B2 JP2000526216A JP2000526216A JP4683724B2 JP 4683724 B2 JP4683724 B2 JP 4683724B2 JP 2000526216 A JP2000526216 A JP 2000526216A JP 2000526216 A JP2000526216 A JP 2000526216A JP 4683724 B2 JP4683724 B2 JP 4683724B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- composition
- emulsion
- surfactant
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 68
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 25
- 210000004666 bacterial spore Anatomy 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title abstract description 35
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 37
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 26
- 239000010452 phosphate Substances 0.000 claims abstract description 26
- 239000004094 surface-active agent Substances 0.000 claims abstract description 26
- 239000007764 o/w emulsion Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 60
- 239000003921 oil Substances 0.000 claims description 38
- 235000019198 oils Nutrition 0.000 claims description 38
- 235000021317 phosphate Nutrition 0.000 claims description 36
- 239000012071 phase Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 14
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 11
- 239000002199 base oil Substances 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 10
- 235000012424 soybean oil Nutrition 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 241000193738 Bacillus anthracis Species 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 5
- 235000019485 Safflower oil Nutrition 0.000 claims description 5
- 235000019486 Sunflower oil Nutrition 0.000 claims description 5
- 239000013504 Triton X-100 Substances 0.000 claims description 5
- 229920004890 Triton X-100 Polymers 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 235000021302 avocado oil Nutrition 0.000 claims description 5
- 239000008163 avocado oil Substances 0.000 claims description 5
- 239000000828 canola oil Substances 0.000 claims description 5
- 235000019519 canola oil Nutrition 0.000 claims description 5
- 235000005687 corn oil Nutrition 0.000 claims description 5
- 239000002285 corn oil Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 235000005713 safflower oil Nutrition 0.000 claims description 5
- 239000003813 safflower oil Substances 0.000 claims description 5
- 229940032094 squalane Drugs 0.000 claims description 5
- 229940038774 squalene oil Drugs 0.000 claims description 5
- 239000002600 sunflower oil Substances 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims 4
- 150000002314 glycerols Chemical class 0.000 claims 4
- -1 squalene oil Substances 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- 239000011782 vitamin Substances 0.000 claims 4
- 229940088594 vitamin Drugs 0.000 claims 4
- 229930003231 vitamin Natural products 0.000 claims 4
- 235000013343 vitamin Nutrition 0.000 claims 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 2
- 239000008158 vegetable oil Substances 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 241000607598 Vibrio Species 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241000193755 Bacillus cereus Species 0.000 description 42
- BOBBYBHJYYJHHQ-UHFFFAOYSA-N 7-tert-butyl-6-(4-chlorophenyl)-2-sulfanylidene-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound CC(C)(C)C1=NC=2NC(=S)NC(=O)C=2C=C1C1=CC=C(Cl)C=C1 BOBBYBHJYYJHHQ-UHFFFAOYSA-N 0.000 description 41
- 210000004215 spore Anatomy 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000000725 suspension Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 230000002779 inactivation Effects 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000001974 tryptic soy broth Substances 0.000 description 9
- 108010050327 trypticase-soy broth Proteins 0.000 description 9
- 210000002421 cell wall Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000446313 Lamella Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 108010008488 Glycylglycine Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940064804 betadine Drugs 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 208000013435 necrotic lesion Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004763 spore germination Effects 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 108010054473 Bacteria oligopeptide permease Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/12—Iodine, e.g. iodophors; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/002,228 US6015832A (en) | 1997-12-31 | 1997-12-31 | Methods of inactivating bacteria including bacterial spores |
| US09/002,228 | 1997-12-31 | ||
| PCT/US1998/027755 WO1999033459A1 (en) | 1997-12-31 | 1998-12-28 | Methods of inactivating bacteria including bacterial spores |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001527041A JP2001527041A (ja) | 2001-12-25 |
| JP4683724B2 true JP4683724B2 (ja) | 2011-05-18 |
Family
ID=21699801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000526216A Expired - Lifetime JP4683724B2 (ja) | 1997-12-31 | 1998-12-28 | 細菌胞子を含めた細菌の不活化方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6015832A (de) |
| EP (1) | EP1041978B1 (de) |
| JP (1) | JP4683724B2 (de) |
| AT (1) | ATE356549T1 (de) |
| AU (1) | AU749817B2 (de) |
| CA (1) | CA2316888C (de) |
| DE (1) | DE69837348T2 (de) |
| HK (1) | HK1031839A1 (de) |
| IL (1) | IL137093A (de) |
| WO (1) | WO1999033459A1 (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524592B2 (en) * | 1997-10-17 | 2003-02-25 | American Home Products Corporation | Veterinary vaccines |
| US7390432B2 (en) * | 1998-06-30 | 2008-06-24 | Sandia Corporation | Enhanced formulations for neutralization of chemical, biological and industrial toxants |
| US6723890B2 (en) | 1998-06-30 | 2004-04-20 | Sandia Corporation | Concentrated formulations and methods for neutralizing chemical and biological toxants |
| US6506803B1 (en) * | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
| US6635676B2 (en) * | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) * | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US20030059839A1 (en) * | 2001-05-22 | 2003-03-27 | Obiso Richard J. | Method for detecting pathogens using immunoassays |
| AU2002367976B2 (en) * | 2001-06-05 | 2007-06-21 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| JP2010209109A (ja) * | 2001-06-25 | 2010-09-24 | Regents Of The Univ Of Michigan | 抗微生物ナノエマルジョンの組成物および方法 |
| MXPA04003603A (es) * | 2001-10-19 | 2005-04-11 | Innovative Constr & Build Mat | Medios de filtracion de aire antipatogenos y dispositivos para manejar aire que tienen capacidades protectoras contra microorganismos infecciosos transportados por el aire. |
| EP1446009A2 (de) * | 2001-11-08 | 2004-08-18 | Merck & Co., Inc. | Verbindungen zur behandlung von anthrax |
| US20040087564A1 (en) * | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
| US20050208083A1 (en) | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
| US8211448B2 (en) * | 2003-07-07 | 2012-07-03 | Nares Ab | Microemulsions and its use for preventing airway diseases |
| ES2297442T3 (es) * | 2003-07-07 | 2008-05-01 | Nares Ab | Microemulsiones y su uso para prevenir enfermedades de las vias respiratorias. |
| US20050100601A1 (en) * | 2003-11-07 | 2005-05-12 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
| EP1851271A1 (de) * | 2005-01-11 | 2007-11-07 | Clean Earth Technologies, LLC | Persäure/peroxid-zusammensetzung und verwendung davon als antimikrobielles mittel und photosensibilisator |
| WO2006110699A1 (en) * | 2005-04-11 | 2006-10-19 | Nanobio Corporation | Quaternary ammonium halides for treatment of infectious conditions |
| WO2008051186A2 (en) | 2005-08-09 | 2008-05-02 | Nanobio Corporation | Nanoemulsion containing compositions having ant i -inflammatory activity |
| US7797337B2 (en) * | 2005-09-29 | 2010-09-14 | Scenera Technologies, Llc | Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource |
| US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
| US9839685B2 (en) * | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
| US20080038295A1 (en) * | 2006-04-13 | 2008-02-14 | Regents Of The University Of Michigan | Compositions and methods for orthopox virus vaccination |
| CA2649457A1 (en) * | 2006-04-13 | 2007-10-25 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| US8741954B2 (en) * | 2007-02-21 | 2014-06-03 | Viratox, L.L.C. | Synergistic enhancement of calcium propionate |
| US8747872B2 (en) * | 2007-05-02 | 2014-06-10 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| JP2011518184A (ja) * | 2008-04-18 | 2011-06-23 | ナノバイオ コーポレーション | ヘルペスウイルス感染の治療方法 |
| EP3023107A1 (de) | 2008-04-21 | 2016-05-25 | Nanobio Corporation | Nanoemulsions-influenza-impfstoff |
| WO2009132343A1 (en) * | 2008-04-25 | 2009-10-29 | Nanobio Corporation | Nanoemulsions for treating onchomycosis |
| JP2011518844A (ja) * | 2008-04-25 | 2011-06-30 | ナノバイオ コーポレーション | 真菌、酵母および糸状菌感染症を治療するためのナノエマルション |
| AU2009293595A1 (en) * | 2008-05-23 | 2010-03-25 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
| US8877208B2 (en) | 2008-05-23 | 2014-11-04 | The Regents Of The University Of Michigan | Multivalent nanoemulsion vaccines |
| EP2349209A2 (de) | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür |
| WO2010042212A2 (en) | 2008-10-10 | 2010-04-15 | Dara Biosciences, Inc. | Methods for treating or preventing pain using spicamycin derivatives |
| WO2010045367A1 (en) * | 2008-10-14 | 2010-04-22 | Dr Pepper/Seven Up, Inc. | Shelf-stable consumable compositions containing probiotic-mimicking elements and methods of preparing and using the same |
| CA2743904A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
| US20100226983A1 (en) * | 2009-01-28 | 2010-09-09 | Nanobio Corporation | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof |
| US8668911B2 (en) | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| JP5771605B2 (ja) | 2009-05-22 | 2015-09-02 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法 |
| EP3020412B1 (de) | 2009-06-16 | 2017-10-11 | The Regents of the University of Michigan | Nanoemulsionsimpfstoffe |
| US20110229512A1 (en) * | 2010-03-19 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating urinary tract infections |
| JP2014520805A (ja) | 2011-07-06 | 2014-08-25 | ナノバイオ コーポレーション | ヒト呼吸器合胞体ウイルスワクチン |
| EP3329936A1 (de) | 2011-08-22 | 2018-06-06 | Nanobio Corporation | Impfstoff gegen den herpes-simplex-virus als nanoemulsion |
| US9561271B2 (en) | 2011-09-09 | 2017-02-07 | Nanobio Corporation | Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine |
| EP2782597B1 (de) | 2011-11-23 | 2022-04-13 | Genocea Biosciences, Inc. | Nukleinsäureimpfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion |
| EP4112076A1 (de) | 2014-10-10 | 2023-01-04 | The Regents of The University of Michigan | Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen |
| ES2905181T3 (es) | 2015-05-01 | 2022-04-07 | Prec Biosciences Inc | Deleción precisa de secuencias cromosómicas in vivo |
| US11173197B2 (en) | 2015-07-07 | 2021-11-16 | Bluewillow Biologics, Inc. | Methods and compositions for nanoemulsion vaccine formulations |
| CA2997909A1 (en) | 2015-09-08 | 2017-03-16 | Precision Biosciences, Inc. | Treatment of retinitis pigmentosa using engineered meganucleases |
| DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| EP3756682B8 (de) | 2015-10-05 | 2022-04-27 | Precision Biosciences, Inc. | Genetisch veränderte zellen mit gen aus konstanter alpha-region modifizierter menschlicher t-zell-rezeptoren |
| CA3009637A1 (en) | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| NZ745936A (en) | 2016-04-27 | 2020-02-28 | Univ Puerto Rico | 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases |
| ES2905791T3 (es) | 2016-05-03 | 2022-04-12 | Prec Biosciences Inc | Nucleasas de ingeniería útiles para el tratamiento de la hemofilia A |
| WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
| EP3519427A4 (de) | 2016-09-28 | 2020-03-11 | Genocea Biosciences Inc. | Verfahren und zusammensetzungen zur behandlung von herpes |
| EP3757120B8 (de) | 2016-10-04 | 2022-06-15 | Precision Biosciences, Inc. | Co-stimulierende domänen zur verwendung bei genetisch veränderten zellen |
| KR102305215B1 (ko) | 2016-10-14 | 2021-09-28 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| CN110769845B (zh) | 2017-04-21 | 2023-08-15 | 精密生物科学公司 | 对pcsk9基因中的识别序列具有特异性的工程化大范围核酸酶 |
| WO2018201144A1 (en) | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| CA3062698A1 (en) | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
| CA3074212A1 (en) * | 2017-08-28 | 2019-03-07 | University Of Louisiana At Lafayette | Method of manufacture for hand-sanitizing lotion with prolonged effectiveness and resulting composition of matter |
| WO2019070856A1 (en) | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS |
| US20200299658A1 (en) | 2017-11-01 | 2020-09-24 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
| US20210393554A1 (en) | 2018-11-15 | 2021-12-23 | Bluewillow Biologics, Inc. | Nanoemulsion compositions having enhanced permeability |
| US11369578B2 (en) | 2018-11-15 | 2022-06-28 | Bluewillow Biologics, Inc. | Persistent topical antimicrobial compositions and methods of using the same |
| EP3898661A1 (de) | 2018-12-21 | 2021-10-27 | Precision BioSciences, Inc. | Genetische modifikation des hydroxysäure-oxidase-1-gens zur behandlung von primärer hyperoxalurie |
| CA3135799A1 (en) | 2019-04-03 | 2020-10-08 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| US20220273715A1 (en) | 2019-07-25 | 2022-09-01 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| AU2020333851A1 (en) | 2019-08-20 | 2022-03-31 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| WO2021113543A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| EP4150068A1 (de) | 2020-05-12 | 2023-03-22 | Precision BioSciences, Inc. | Behandlung von retinitis pigmentosa mit verbesserten manipulierten meganukleasen |
| EP4192875A1 (de) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antikörper und fragmente spezifisch für b-zellreifungsantigen und verwendungen davon |
| WO2022035309A1 (en) * | 2020-08-14 | 2022-02-17 | Universiti Putra Malaysia | Nano emulsion composition having antimicrobial properties |
| AU2021329403A1 (en) | 2020-08-21 | 2023-05-04 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
| KR20230118841A (ko) | 2020-11-12 | 2023-08-14 | 프리시젼 바이오사이언시스 인코포레이티드 | 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제 |
| WO2022150616A1 (en) | 2021-01-08 | 2022-07-14 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene |
| EP4284823A1 (de) | 2021-01-28 | 2023-12-06 | Precision BioSciences, Inc. | Modulation der tgf-beta-signalisierung in genetisch modifizierten eukaryotischen zellen |
| EP4326862A1 (de) | 2021-04-22 | 2024-02-28 | Precision Biosciences, Inc. | Manipulierte meganukleasen gegen menschliche mitochondriale genome |
| EP4326861A1 (de) | 2021-04-22 | 2024-02-28 | Precision Biosciences, Inc. | Manipulierte meganukleasen gegen menschliche mitochondriale genome |
| AU2022368911A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| AU2022371430A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58118518A (ja) * | 1982-01-04 | 1983-07-14 | ニューヨーク・ブラッド・センター・インコーポレーテッド | 脱パイロジエン方法 |
| JPS6051116A (ja) * | 1983-07-14 | 1985-03-22 | ニユ−ヨ−ク ブラツド センタ−，インコ−ポレイテイド | 脂質含有ウイルスを含まない蛋白質含有組成物及びその製造方法 |
| JPH03500051A (ja) * | 1988-06-22 | 1991-01-10 | アプライド マイクロバイオロジー，インコーポレイテッド | 強化広域殺菌剤として使用されるナイシン組成物 |
| JPH07126109A (ja) * | 1993-11-01 | 1995-05-16 | Koki Bussan Kk | 消毒剤 |
| JPH07196408A (ja) * | 1993-12-28 | 1995-08-01 | Amano Pharmaceut Co Ltd | 抗菌性組成物 |
| WO1995031966A1 (en) * | 1994-05-20 | 1995-11-30 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
| WO1996033725A1 (en) * | 1995-04-24 | 1996-10-31 | Novavax, Inc. | Solvent detergent emulsions having antiviral activity |
| JPH09278610A (ja) * | 1996-04-16 | 1997-10-28 | Ofutekusu:Kk | 有害微生物防除用組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
| US4909940A (en) * | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
| US5156973A (en) * | 1988-11-23 | 1992-10-20 | Edward Shanbrom | Antiviral blood sampling process and apparatus |
| US5547677A (en) * | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
| US5549901A (en) * | 1994-05-20 | 1996-08-27 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
-
1997
- 1997-12-31 US US09/002,228 patent/US6015832A/en not_active Expired - Lifetime
-
1998
- 1998-12-28 DE DE69837348T patent/DE69837348T2/de not_active Expired - Lifetime
- 1998-12-28 IL IL137093A patent/IL137093A/en not_active IP Right Cessation
- 1998-12-28 WO PCT/US1998/027755 patent/WO1999033459A1/en active IP Right Grant
- 1998-12-28 EP EP98964997A patent/EP1041978B1/de not_active Expired - Lifetime
- 1998-12-28 CA CA002316888A patent/CA2316888C/en not_active Expired - Lifetime
- 1998-12-28 JP JP2000526216A patent/JP4683724B2/ja not_active Expired - Lifetime
- 1998-12-28 AT AT98964997T patent/ATE356549T1/de not_active IP Right Cessation
- 1998-12-28 AU AU20198/99A patent/AU749817B2/en not_active Expired
-
2001
- 2001-04-11 HK HK01102591A patent/HK1031839A1/xx not_active IP Right Cessation
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58118518A (ja) * | 1982-01-04 | 1983-07-14 | ニューヨーク・ブラッド・センター・インコーポレーテッド | 脱パイロジエン方法 |
| JPS6051116A (ja) * | 1983-07-14 | 1985-03-22 | ニユ−ヨ−ク ブラツド センタ−，インコ−ポレイテイド | 脂質含有ウイルスを含まない蛋白質含有組成物及びその製造方法 |
| JPH03500051A (ja) * | 1988-06-22 | 1991-01-10 | アプライド マイクロバイオロジー，インコーポレイテッド | 強化広域殺菌剤として使用されるナイシン組成物 |
| JPH07126109A (ja) * | 1993-11-01 | 1995-05-16 | Koki Bussan Kk | 消毒剤 |
| JPH07196408A (ja) * | 1993-12-28 | 1995-08-01 | Amano Pharmaceut Co Ltd | 抗菌性組成物 |
| WO1995031966A1 (en) * | 1994-05-20 | 1995-11-30 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
| WO1996033725A1 (en) * | 1995-04-24 | 1996-10-31 | Novavax, Inc. | Solvent detergent emulsions having antiviral activity |
| JPH09278610A (ja) * | 1996-04-16 | 1997-10-28 | Ofutekusu:Kk | 有害微生物防除用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69837348T2 (de) | 2007-11-29 |
| IL137093A0 (en) | 2001-06-14 |
| IL137093A (en) | 2007-03-08 |
| US6015832A (en) | 2000-01-18 |
| AU749817B2 (en) | 2002-07-04 |
| JP2001527041A (ja) | 2001-12-25 |
| AU2019899A (en) | 1999-07-19 |
| EP1041978A4 (de) | 2004-05-19 |
| HK1031839A1 (en) | 2001-06-29 |
| DE69837348D1 (de) | 2007-04-26 |
| EP1041978A1 (de) | 2000-10-11 |
| WO1999033459A1 (en) | 1999-07-08 |
| ATE356549T1 (de) | 2007-04-15 |
| CA2316888C (en) | 2007-06-19 |
| EP1041978B1 (de) | 2007-03-14 |
| CA2316888A1 (en) | 1999-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4683724B2 (ja) | 細菌胞子を含めた細菌の不活化方法 | |
| EP2364709B1 (de) | Antimikrobielle Zusammensetzung und Verfahren zu ihrer Anwendung | |
| US5549901A (en) | Antimicrobial oil-in-water emulsions | |
| US7767216B2 (en) | Antimicrobial compositions and methods of use | |
| US5618840A (en) | Antibacterial oil-in-water emulsions | |
| US6635676B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
| US6559189B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
| US8232320B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
| US7655252B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
| AU2002350587A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
| JPH11505215A (ja) | 抗ビールス活性を有する溶媒洗浄剤エマルジョン | |
| JPH09124503A (ja) | アミチアマイシン類の注射用の抗菌性組成物 | |
| JP2010209109A (ja) | 抗微生物ナノエマルジョンの組成物および方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050719 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091119 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100706 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110125 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110208 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140218 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |